A 10-marker metabolic score is linked to disease risk and function. Examine the human evidence, intervention results and validation gaps.
On October 30, 2026, Agência FAPESP reported on a personalized metabolic-health score presented by Joris Deelen of Leiden University Medical Center at FAPESP Week Netherlands. The meeting took place at Leiden University from October 27 to 29, 2026.
The central finding is that a blood-based metabolic score was associated with mortality and several dimensions of healthy aging, rather than simply with a person's age. Agência FAPESP and Medical Xpress reported links with cardiometabolic disease, cognitive function, lung capacity and handgrip strength. Taken together, those results position the score as a possible indicator of health in middle age and risk of functional decline. The researchers present it as a metabolic-health indicator rather than a direct measurement of biological age.
Study setting: Human participants. This was human blood-data research, with a separate lifestyle-intervention analysis, not an in vitro or animal-model study.
According to Agência FAPESP, the team analyzed blood data from 44,000 volunteers across 12 European studies. Researchers measured more than 200 substances, and 5,500 deaths were recorded during follow-up. The team included scientists from the Max Planck Institute for Biology of Ageing.
This large dataset provided the starting point for a simpler score. The researchers used Dutch population data to personalize the results and reduced the panel to 10 markers already familiar in clinical practice. They also changed its direction so that higher scores indicate better health.
The useful distinction is between the breadth of the original analysis and the size of the revised panel. The researchers did not report a score that requires every substance from the initial screening. They aimed to condense that information into a smaller set of measurements.
Here, “personalized” refers to the reported calibration using Dutch population data. That is the concrete customization described in the account. Keeping that definition attached to the term makes the research easier to assess.
The smaller panel is the central practical idea in the report. It asks whether a compact summary of familiar measurements can represent information first identified through much broader blood profiling. That makes the study relevant to discussions about usable biomarkers, not just to the technical ability to measure many substances at once.
The reported disease associations included diabetes, heart attack and stroke. The reports also linked the score to cognition, lung capacity and grip strength. These outcomes give the study a broader healthy-aging focus than mortality alone.
That breadth matters to the question the researchers are asking. A risk indicator that relates to both disease and functional measures could be useful for studying healthspan, meaning the period of life spent in good health. In this report, the functional measures are part of the evidence connecting metabolic status with that wider concept.
Deelen told FAPESP that a one-point increase on the revised scale corresponded to an average 14-year delay in the onset of a first cardiometabolic disease. This is the report's most striking numerical association. It describes the relationship between score differences and disease onset in the research.
Readers comparing this work with other tests can start by separating a test's target from its label. For this score, the reported targets include metabolic health and disease risk. Asking which outcome a score tracks is more useful than assuming all aging-related tests answer the same question.
It also helps to separate the outcomes within this study. Mortality asks about survival, while a first cardiometabolic disease concerns the onset of illness. Cognition, lung capacity and grip strength bring function into the picture. A clear account of the score should preserve these separate endpoints rather than compress them into a single claim of better aging.
A secondary account of the research describes an analysis of 2,404 participants from the Leiden Longevity Study. It also reports a 13-week lifestyle intervention involving 164 older adults. These are distinct pieces of evidence from the larger dataset described in the event coverage.
The intervention addressed a different question from the population analyses: whether the score would shift during a lifestyle program. That distinction is useful because an association across people and a change within a person answer different research questions. The intervention results need to be judged on their own design and outcomes.
For the intervention, there are also separate outcomes to follow: the combined score and the individual metabolic measures. The report names fasting insulin, triglycerides and body composition among the latter. A careful reading should specify which result is being discussed rather than treating the score and each of its related measures as interchangeable.
Agência FAPESP also reported that the researchers' analysis attributed about 40% of score variation to heredity and 60% to lifestyle and environmental factors. Smoking was the strongest negative behavioral factor among those analyzed.
This part of the analysis concerns why people may have different scores. The disease analyses concern what those scores are associated with. Both are relevant to understanding the indicator, but they address different aspects of the research.
For readers, the immediate use of this research is to evaluate what a blood-score claim is actually supported by. Look for the measured outcome, the population used to develop the model and evidence that applying it changes care for the better. The same distinction matters when connecting an aging marker with a meaningful health outcome. Personal decisions about testing belong in a discussion with a qualified healthcare professional.
The next research priority should be prospective validation in more diverse populations, followed by controlled studies testing whether care guided by the score improves disease or functional outcomes rather than merely changing a blood-based number.
Turning a blood-score association into a promise of healthier aging overstates the evidence, a risk AgeAmaze addresses through research-led explanations. Its reporting helps skeptical adults assess biological-age and emerging-intervention claims by keeping the scientific findings and their limitations visible, rather than presenting early results as established benefits.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
